The Role of Kinase Modulators in Cellular Senescence for Use in Cancer Treatment.
| Autor: | Lee CS; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, 501 Jinju-daero, Jinju, Gyeongnam 52828, Korea. changsup@gnu.ac.kr., Baek J; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, 501 Jinju-daero, Jinju, Gyeongnam 52828, Korea. qorwnghk2006@naver.com., Han SY; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, 501 Jinju-daero, Jinju, Gyeongnam 52828, Korea. syhan@gnu.ac.kr. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Molecules (Basel, Switzerland) [Molecules] 2017 Aug 25; Vol. 22 (9). Date of Electronic Publication: 2017 Aug 25. |
| DOI: | 10.3390/molecules22091411 |
| Abstrakt: | Recently, more than 30 small molecules and eight monoclonal antibodies that modulate kinase signaling have been approved for the treatment of several pathological conditions, including cancer, idiopathic pulmonary fibrosis, and rheumatoid arthritis. Among them, kinase modulators have been a primary focus for use in cancer treatment. Cellular senescence is believed to protect cells from tumorigenesis by irreversibly halting cell cycle progression and avoiding the growth of damaged cells and tissues. Senescence can also contribute to tumor suppression and be utilized as a mechanism by anti-cancer agents. Although the role of kinase modulators in cancer treatment and their effects on senescence in tumor development have been extensively studied, the relationship between kinase modulators for cancer treatment and senescence has not been fully discussed. In this review, we discuss the pro- and anti-tumorigenesis functions of senescence and summarize the key roles of kinase modulators in the regulation of senescence against tumors. Competing Interests: The authors declare no conflict of interest. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|